layoffs – Talk Bio

Merck Begins Layoffs in New Jersey as Part of $3 Billion Cost-Cutting Plan

1 week ago talkbio0Tagged cost-cutting, Keytruda, layoffs, Merck & Co., New Jersey, Pharma Industry, restructuring, WARN notice

Merck & Co.; New Jersey; layoffs; pharma industry; cost-cutting; Keytruda; restructuring; WARN notice

Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends

2 weeks ago talkbio0Tagged Bicycle, Financial cost, genentech, layoffs, Partnership, R&D, strategic realignment, Workforce reduction

Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment

BioNTech to Cut 90 More US Jobs Amid Strategic Realignment

2 weeks ago talkbio0Tagged BioNTech, Cambridge, Cell Therapy, Gaithersburg, layoffs, Market, pipeline focus, post-COVID, R&D, strategic alignment

BioNTech; layoffs; job cuts; R&D; pipeline focus; Gaithersburg; Cambridge; cell therapy; post-COVID market; strategic alignment

Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring

2 weeks ago talkbio0Tagged Bayer, Bill Anderson, cost-cutting, layoffs, Pharma, restructuring

Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry

Merck to Lay Off 6,000 Employees, Reduce Workforce by 8% in $3B Cost-Cutting Move

3 weeks ago talkbio0Tagged cost-cutting, Gardasil, Keytruda, layoffs, Merck, restructuring

Merck; layoffs; cost-cutting; restructuring; pharmaceuticals; job cuts; Keytruda; Gardasil; workforce reduction

Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push

3 weeks ago talkbio0Tagged Biotechnology, COVID-19 Vaccines, Financial savings, layoffs, Moderna, Stéphane Bancel

Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine

Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

4 weeks ago talkbio0Tagged Adaptimmune, Afami-cel, biotech workforce, cell therapy sale, layoffs, restructuring, Tecelra, U.S., WorldMeds

Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel

Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies

4 weeks ago talkbio0Tagged 30%, Anemia, BAG3-associated, cardiovascular gene therapy, Deficiency of pyruvate kinase, Dependovirus, Financial cost, Glycogen Storage Disease Type IIb, Kresladi, layoffs, PKP2-associated cardiomyopathy, restructuring, Rocket

Rocket Pharmaceuticals; layoffs; restructuring; 30% workforce reduction; cardiovascular gene therapy; adeno-associated virus (AAV); Danon disease; PKP2-associated cardiomyopathy; BAG3-associated dilated cardiomyopathy; operating cost reduction; Fanconi Anemia; Pyruvate Kinase Deficiency; KRESLADI